1100 13th Street, NW, Suite 750Washington, DC 20005202.887.6400Customer Service: 800.544.0155
All Contents © 2019The Kiplinger Washington Editors
Most of the buy-and-hold crowd tends to steer clear of biotech stocks, and for good reason. Biotechnology companies can be uncomfortably risky. Far too many horror stories of failed drug trials or the...
When investors think of biotech stocks, visions of Amgen (AMGN) and Gilead (
Morningstar is in the middle of revamping its fund analysts' methodology. Can they beat the indices?
More Investing News »